References

1. Gertz M, Adams D et al., BMC Fam Pract. 2020 Sep 23;21(1):198.
2. Conceição I et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9.
3. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(suppl 7):S107–S112.
4. Donnelly JP & Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84(12 suppl 3):12–26.
5. Adams D, Ando Y et al., J Neurol. 2021 Jun;268(6):2109-212.
6. Monteiro C, Mesgazardeh JS et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019 Jun 20;4(12):e126526
7. Amyloidosis Foundation. Understanding the patient voice in hereditary transthyretin-mediated amyloidosis (ATTR amyloidosis). Available at: https://www.amyloidosissupport.org/support_groups/fam_isabell_attr.pdf. Accessed April 2020.